Skip to main content
SpringerLink
Log in

Wirkverlust und „Therapieresistenz“

  • Chapter
Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 86 Accesses

Zusammenfassung

In der Mehrzahl der Fälle gelingt es, mit einer der verschiedenen möglichen Strategien der Ersteinstellung eines Patienten mit idiopathischem Parkinson-Syndrom zu einem befriedigenden Therapieresultat zu gelangen. Bei L-Dopa-Monotherapie wird in Abhängigkeit von der gewählten Dosis innerhalb des ersten Behandlungsjahres bei bis zu 90% der Patienten ein ausreichender Effekt erzielt (Shaw et al. 1980, Poewe et al. 1986a, s. auch Tabelle 10.2). Ähnlich ist die Situation bei Kombinationsbehandlung von L-Dopa mit einem Dopamin-(DA)-Agonisten (Rinne 1989), während nur knapp 60% auf Monotherapie mit einem DA-Agonisten im ersten Jahr hinlänglich gut ansprechen (Lees und Stern 1983, Rascol et al. 1984). Amantadin als Monotherapie oder in Kombination mit einem Anticholinergikum führte in 70% zum erwünschten Effekt (Schwab et al. 1969, Parkes et al. 1970).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Agid Y, Ruberg M, Dubois B, Javoy-Agid F (1983) Biochemical substrates of mental disturbances in Parkinson’s disease. Adv Neurol 40: 211–218

    Google Scholar 

  • Bass H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G (1997) Catechol-O-methyltransferase inhibition with tolcapone reduces the „wearing off“ phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63: 421–428

    Article  Google Scholar 

  • Barbeau A (1976) Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 33: 333–338

    Article  PubMed  CAS  Google Scholar 

  • Barbeau A, Roy M (1976) Six-year results of treatment with levodopa plus benserazide in Parkinson’s disease. Neurology 26: 399–404

    Article  PubMed  CAS  Google Scholar 

  • Battistin L Meneghetti G, Rigotti S, Saia A (1978) A long-term treatment of Parkinson’s disease with L-Dopa and doipa-decarboxylase inhibitor: therapeutic results and side-effects. Acta Neurol Scand 57: 186–192

    Article  PubMed  CAS  Google Scholar 

  • Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with „Madopar“ and 1-deprenyl in Parkinson’s disease: a long-term study. Lancet i: 343–349

    Google Scholar 

  • Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y (1987) Does longterm aggravation of Parkinson’s disease result from nondopamin-ergic lesions? Neurology 37: 1539–1542

    Article  PubMed  CAS  Google Scholar 

  • Butzer JF, Silver DE, Sahs AL (1975) Amantadine in Parkinson’s disease. Neurology 25:603–606

    Article  PubMed  CAS  Google Scholar 

  • Carter JH, Nutt JG, Woodward WR, Hatcher L, Trotman L (1989) Amount and distribution of dietary protein affects the clinical response to levodopa. Neurology 39: 552–556

    Article  PubMed  CAS  Google Scholar 

  • Cedarbaum JM (1989) The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol 12: 147–166

    Article  PubMed  CAS  Google Scholar 

  • Davis TL, Roznoski M, Burns RS (1995) Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 18: 333–337

    Article  PubMed  CAS  Google Scholar 

  • Davis TL, Roznoski M, Burns RS (1995) Effects of tolcapone in Parkinson’s patients taking L-di-hydroxyphenylalantine/carbidopoa and selegiline. Mov Disord 10: 349–351

    Article  PubMed  CAS  Google Scholar 

  • Duvoisin RC (1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17: 124–136

    Article  PubMed  CAS  Google Scholar 

  • Erni W, Held K (1987) The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 27 [Suppl 1]: 21–27

    Article  PubMed  CAS  Google Scholar 

  • Evans MA, Broe GA, Triggs EJ, Cheung M, Creasy H, Paull PD (1981) Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 31: 1288–1294

    Article  PubMed  CAS  Google Scholar 

  • Fischer PA, Schneider E, Jacobi P (1984) Ergebnisse der medikamentösen Parkinson-Therapie. Modifizierende und limitierende Faktoren. In: Fischer PA (Hrsg) Parkinson plus. Springer, Berlin Heidelberg New York, S 4–7

    Chapter  Google Scholar 

  • Frankel JP, Kempster PA, Bovingdon M, Webster R, Lees AJ, Stern GM (1989) The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 52: 1063–1067

    Article  PubMed  CAS  Google Scholar 

  • Frankel JP, Lees AJ, Kempster PA, Stern GM (1990) Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 53: 96–101

    Article  PubMed  CAS  Google Scholar 

  • Friedman JH, Lannon MC (1990) Clozapine-re-sponsive tremor in Parkinson’s disease. Mov Disord 5: 225–229

    Article  PubMed  CAS  Google Scholar 

  • Gancher ST, Nutt JG, Woodward W (1988) Response to brief levodopa infusions in Parkinsonian patients with and without motor fluctuations. Neurology 38: 712–716

    Article  PubMed  CAS  Google Scholar 

  • Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51: 745–752

    Article  PubMed  CAS  Google Scholar 

  • Golbe LI (1988) Deprenyl as symptomatic therapy in Parkinson’s disease. Clin Neuropharmacol 11: 387–400

    Article  PubMed  CAS  Google Scholar 

  • Hughes AJ, Lees AJ, Stern GM (1990) Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 336: 32–34

    Article  PubMed  CAS  Google Scholar 

  • Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44: 77–80

    Article  PubMed  CAS  Google Scholar 

  • Kempster PA, Gibb WRG, Stern GM, Lees AJ (1989a) Asymmetry of substantia nigra neuronal loss in Parkinson’s disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 52: 72–76

    Article  PubMed  CAS  Google Scholar 

  • Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM (1989b) Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52: 718–723

    Article  PubMed  CAS  Google Scholar 

  • Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F (1998) Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 13: 46–51

    Article  PubMed  CAS  Google Scholar 

  • Kurlan R, Rubin AJ, Miller C et al. (1986) Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20: 262–265

    Article  PubMed  CAS  Google Scholar 

  • Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, Lewitt P, Chernik DA, Dorflinger EE, Yoo K (1997) Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 48: 81–87

    Article  PubMed  CAS  Google Scholar 

  • Lang AE (1984) Treatment of Parkinson’s disease with agents other than levodopa and dopamine agonists: controversies and new approaches. Can J Neurol Sci 2: 210–220

    Google Scholar 

  • Lee JE, Sweet RD, Mcdowell FH (1971 ) Treatment of parkinsonism with levodopa: follow-up after 2 years of treatment. Ann Intern Med 75: 703–708

    PubMed  CAS  Google Scholar 

  • Leenders KL, Poewe WH, Palmer AJ, Brenton D, Frackowiack RSJ (1986a) Inhibition of L-18(F)-fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20: 258–261

    Article  PubMed  CAS  Google Scholar 

  • Leenders KL, Palmer AJ, Quinn NP et al. (1986b) Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49: 853–860

    Article  PubMed  CAS  Google Scholar 

  • Lees AJ, Stern GM (1983) Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson’s disease. Adv Neurol 37: 17–21

    PubMed  Google Scholar 

  • Liebermann AN, Goldstein M, Leibowitz M, Gopinathan G, Neophytides A, Hiesiger E, Nelson J, Walker R (1984) Long-term treatment with pergolide: decreased efficacy with time. Neurology 34: 223–226

    Article  Google Scholar 

  • Limousin P, Pollak P, Gervason-Tournier CL, Hommel M, Perret JE (1993) Ro 40-7592, a COMT-inhibitor, plus levodopa in Parkinson’s disease. Lancet 341 (8860): 1605

    Article  PubMed  CAS  Google Scholar 

  • Limousin P, Pollak P, Pfefen JP, Tournier-Gerva-Son CL, Dubuis R, Perret JE (1995) Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson’s disease. Clin Neuropharmacol 18: 258–265

    Article  PubMed  CAS  Google Scholar 

  • Markham CH, Treciokas LJ, Diamond SG (1974) Parkinson’s disease and levodopa: a five year follow up and review. West J Med 121: 188–206

    PubMed  CAS  Google Scholar 

  • Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet i: 345–349

    Article  Google Scholar 

  • Mcdowell FH, Sweet R (1979) Ten-year follow-up study of levodopa-treated patients with Parkinson’s disease. Adv Neurol 24: 475–480

    Google Scholar 

  • Mena I, Cotzias GC (1978) Protein intake and treatment of Parkinson’s disease with levodopa. N Engl J Med 292: 131–184

    Google Scholar 

  • Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A (1994) Effect of entacapone, a peripherally acting catechol-O-methyltrans-ferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 57: 186–189

    Article  PubMed  CAS  Google Scholar 

  • Mouradian MM, Chase TN (1988) Central mechanisms and levodopa response fluctuations in Parkinson’s disease. Clin Neuropharmacol 11: 378–385

    Article  PubMed  CAS  Google Scholar 

  • Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN (1988) Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, part 2. Ann Neurol 24: 372–378

    Article  PubMed  CAS  Google Scholar 

  • Nutt JG, Fellman JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmol 7: 35–49

    Article  CAS  Google Scholar 

  • Nutt JG, Woodward WA, Hammerstad JP, Carter JH, Anderson JL (1984) The „on-off“ phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N Engl J Med 310: 483–488

    Article  PubMed  CAS  Google Scholar 

  • Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammer-Stad JP, Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44: 913–919

    Article  PubMed  CAS  Google Scholar 

  • Obeso J, Luquin MR, Martinez-Lage JM (1986) Intravenous lisuride corrects oscillations in motor performance in Parkinson’s disease. Ann Neurol 19: 31–35

    Article  PubMed  CAS  Google Scholar 

  • Obeso JA, Luquin MR, Martinez-Lage JM (1988) Subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson’s disease. J Neural Transm [Suppl] 27: 17–25

    CAS  Google Scholar 

  • Oertel WH, Gasser T, Ippisch R, Trenkwalder C, Poewe WH (1989) Apomorphine test for dopaminergic responsiveness. Lancet i: 1263

    Google Scholar 

  • Ordenstein L (1967) Sur la Daralvsie aaitante e la sclérose en Dlaque généralisé. Martinet, Paris

    Google Scholar 

  • Pakkenberg H, Pakkenberg B (1986) Clozapine in the treatment of tremor. Acta Neurol Scand 73: 295–297

    Article  PubMed  CAS  Google Scholar 

  • Parkes JD, Zilkha KJ, Calver DM, Knill-Jones RP (1970) Controlled trial of amantadine hydrochloride in Parkinson’s disease. Lancet i: 259–262

    Article  Google Scholar 

  • Parkes JD, Baxter RCH, Curzor G, Knill-Jones RP, Knott PJ, Marsden CD, Tattersall R, Vollum B (1971) Treatment of Parkinson’s disease with amantadine and levodopa. Lancet i: 1083–1085

    Article  Google Scholar 

  • Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 42 (5): 747–755

    Article  Google Scholar 

  • Pincus JH, Barry K (1987) Influence of dietary protein on motor fluctuations in Parkinson’s disease. Arch Neurol 44: 270–272

    Article  PubMed  CAS  Google Scholar 

  • Pincus JH, Barry K (1988) Protein redistribution diet restores motor function in patients with dopa-resistant „off“ periods. Neurology 38: 481–483

    Article  PubMed  CAS  Google Scholar 

  • Poewe W, Kleedorfer B, Wagner M, Benke T, Gasser T, Oertel W (1989a) Side-effects of subcutaneous apomorphine in Parkinson’s disease. Lancet i: 1084–1085

    Article  Google Scholar 

  • Poewe WH, Lees AJ, Stern GM (1986a) Low-dose L-Dopa therapy in Parkinson’s disease: a 6 year follow up study. Neurology 36: 1528–1530

    Article  PubMed  CAS  Google Scholar 

  • Poewe WH, Lees AJ, Stern GM (1986b) Treatment of motor fluctuations in sustained release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 9: 430–439

    Article  PubMed  CAS  Google Scholar 

  • Poewe WH, Kleedorfer B, Gerstenbrand F (1989a) Therapeutische Erfahrungen mit einem slow-release-Präparat von L-Dopa (Madopar HBS) bei Patienten mit fortgeschrittener Parkinson-Krankheit. Nervenarzt 60: 294–298

    PubMed  CAS  Google Scholar 

  • Poewe WH, Kleedorfer B, Gerstenbrand F, Oertel WH (1989b) Die Behandlung von Parkinson-Patienten mit L-Dopa-Wirkungsfluktuation mittels subkutanen Apomorphingaben. Akt Neurol 16: 73–77

    Article  Google Scholar 

  • Quinn N (1989) Multiple system atrophy — the nature of the beast. J Neurol Neurosurg Psychiatry [Suppl]: 78–89

    Google Scholar 

  • Quinn N, Parkes JD, Marsden CD (1984) Control of on-off phenomena by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136

    Article  PubMed  CAS  Google Scholar 

  • Rajput AH, Stern W, Laverty WH (1984) Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 34: 991–996

    Article  PubMed  CAS  Google Scholar 

  • Rascol A, Montrastuc JL, Rascol O (1984) Should dopamine agonists be given early or late in the treatment of Parkinson’s disease?. Can J Neurol Sci 11: 229–232

    PubMed  CAS  Google Scholar 

  • Riley D, Lang AE (1988) Practical application of a low protein diet for Parkinson’s disease. Neurology 38: 1026–1031

    Article  PubMed  CAS  Google Scholar 

  • Rinne UK (1987) Dopamine agonists as primary treatment in Parkinson’s disease. Adv Neurol 45: 519–524

    PubMed  CAS  Google Scholar 

  • Rinne UR (1989) Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 39: 336–339

    Article  PubMed  CAS  Google Scholar 

  • Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN (1993) Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 43: 2685–2688

    Article  PubMed  CAS  Google Scholar 

  • Ruottinen HM, Rinne UK (1996a) Entacapone prolongs levodopa response in a one month double-blind study in parkinsonian patients with levodopa related flucuations. J Neurol Neurosurg Psychiatry 60: 36–40

    Article  PubMed  CAS  Google Scholar 

  • Ruottinen HM, Rinne UK (1996b) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease. Clin Neuropharmacol 19: 283–296

    Article  PubMed  CAS  Google Scholar 

  • Sage JL, Trookin S, Sonsalla PK, Heikkila R, Duvoisin RC (1988) Long-term duodenal infusion of levodopa for motor fluctuations in Parkinsonism. Ann Neurol 24: 87–89

    Article  PubMed  CAS  Google Scholar 

  • Schwab RS, England AC, Poskanzer DL, Young RR (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208: 1168

    Article  CAS  Google Scholar 

  • Shaw KM, Lees AJ, Stern GM (1980) The impact of treatment with Levodopa on Parkinson’s disease. Q J Med 49: 283–293

    PubMed  CAS  Google Scholar 

  • Shoulson I, Glaubiger GA, Chase TN (1975) „On-off“-response. Clinical and biochemical correlations during oral and intravenous levodopa adminstration in parkinsonian patients. Neurology 25: 1144–1148

    Article  PubMed  CAS  Google Scholar 

  • Stibe CMH, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off-oscillations. Lancet i: 403–406

    Article  Google Scholar 

  • Stocchi F, Ruggieri S, Antonini A et al. (1988) Subuctaneous lisuride infusion in Parkinson’s disease: clinical results using different modes of administration. J Neural Transm 27: 27–33

    CAS  Google Scholar 

  • Stocchi F, Ruggieri S, Braurante L, De Pandis F, Agnoli A (1992) Intrajejunal infusion of L-Dopa methylester. Proceedings of the European Conference on Parkinson’s Disease and Extrapyramidal Disorders, Rome, July 10–14, 1990. J Libbey

    Google Scholar 

  • Sweet RD, Mcdowell FH (1975) Five years treatment of Parkinson’s disease with levodopa: therapeutic results and survival of 100 patients. Ann Intern Med 83: 456–463

    PubMed  CAS  Google Scholar 

  • The Parkinson Study Group (1989) Effect of de-prenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371

    Article  Google Scholar 

  • Timberlake WH, Vance MA (1978) Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann Neurol 3: 119–128

    Article  PubMed  CAS  Google Scholar 

  • Vaamonde J, Luquin MR, Obeso JA (1992) Subcutaneous lisuride infusion in Parkinson’s disease: response to chronic ad ministration in 34 patients. Proceedings of the European Conference on Parkinson’s Disease and Extrapyramidal Disorders, Rome, July 10–14, 1990. J Libbey

    Google Scholar 

  • Wade LA, Katzman A (1975) Synthetic amino acids and the nature of levodopa transport at the blood-brain barrier. J Neurochem 25: 837–842

    Article  PubMed  CAS  Google Scholar 

  • Wade DN, Mearrick PT, Morris JL (1973) Active transport of L-Dopa in the intestine. Nature 242: 463–465

    Article  PubMed  CAS  Google Scholar 

  • Wade DN, Mearrick PT, Burkett et al. (1974) Variability of levodopa absorption in man. Aust NZ J Med 4: 138–143

    Article  CAS  Google Scholar 

  • Yahr MD (1976) Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Edi-tiones Roche, Basel, pp 435–443

    Google Scholar 

  • Yeh KC, August TF, Bush DF et al. (1989) Pharmacokinetics and bioavailability of Sinement CR: a summary of human studies. Neurology 39: 25–38

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. Poewe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Poewe, W. (1999). Wirkverlust und „Therapieresistenz“. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6400-6_39

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7315-2

  • Online ISBN: 978-3-7091-6400-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation